Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.
Oncolytics Biotech is developing an oncolytic reovirus therapy (Reolysin, Reosyn) for the potential treatment of a variety of Ras-mediated cancers, including glioma and medulloblastoma, pancreatic, prostate, breast, lung, colon, bladder, ovarian and hematological cancers, and melanoma and childhood sarcoma. Phase I/II clinical trials in recurrent malignant glioma began in 2002.